Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Megan GreallyJoanne F ChouWalid K ChatilaMatthew MargolisMarinela CapanuJaclyn F HechtmanYaelle TuvyRitika KundraFoysal DaianMarc LadanyiDavid P KelsenDavid H IlsonMichael F BergerLaura H TangDavid B SolitLuis A DiazNikolaus SchultzYelena Y JanjigianGeoffrey Y KuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
In patients with advanced EGC, heavily pretreated patients, those with high-volume disease and/or poor PS were less likely to benefit from ICI. irAEs were associated with improved OS. TMB correlated with improved survival, but this association was not observed when MSI-high patients were excluded.